# SCIENTIFIC PROGRAMME (as of March 26, 2014)

**SATURDAY, MAY 31, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 13:30</td>
<td>Educational Symposium (Sponsored)</td>
<td>Francisco Grande-Covian Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>Educational Symposium (Sponsored)</td>
<td>Francisco Grande-Covian Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td>Educational Symposium (Sponsored)</td>
<td>Francisco Grande-Covian Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>18:00 - 19:30</td>
<td>Opening Ceremony including the Anitschkow Lecture</td>
<td>Anitschkow Hall</td>
</tr>
<tr>
<td></td>
<td>Speaker: <em>Prof. John Kastelein, the Netherlands</em></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>08:30</td>
<td>ROLE OF MICROBIOTA IN ATHEROSCLEROSIS</td>
<td>Fredrik Bäckhed, Sweden</td>
</tr>
<tr>
<td>09:00</td>
<td>IMMUNITY IN ATHEROSCLEROSIAN</td>
<td>Ira Tabas, USA</td>
</tr>
<tr>
<td>09:30</td>
<td>VACCINATION AGAINST ATHEROSCLEROSIAN</td>
<td>Johan Kuiper, Netherlands</td>
</tr>
<tr>
<td>10:00</td>
<td>ROLE OF microRNAs IN ATHEROSCLEROSIAN</td>
<td>Carlos Fernández-Hernando, USA</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break, Exhibition &amp; Poster Viewing</td>
<td></td>
</tr>
</tbody>
</table>
11:00 – 12:30  Workshop Session:  
Amador Schuller Hall  
Track 1: Vascular biology of the arterial wall  
1.2 IMMUNOLOGY OF ATHEROSCLEROSIS  
Chairs: Jesus Egido, Spain  
Danilo Norata, Italy

11:00  B CELLS AND HUMORAL IMMUNITY IN ATHEROSCLEROSIS  
Christoph Binder, Austria

11:25  DENDRITIC CELLS  
Alma Zernecke, Germany

11:50  THE ROLE OF INNATE IMMUNE RECEPTOR NOD2 IN ATHEROSCLEROSIS  
Zhang, X., Sweden

12:03  MACROPHAGE-SPECIFIC INACTIVATION OF THE NUCLEAR RECEPTOR ROR-ALPHA LEADS TO INCREASED ATHEROSCLEROSIS IN MOUSE  
Molendi-Coste, O., France

12:16  NON-INVASIVE IN VIVO IMAGING OF PERIPHERAL MONONUCLEAR CELL MIGRATION TO ATHEROSCLEROSIS IN HUMANS  
vander Valk, F., Netherlands
**SUNDAY, JUNE 1, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>Workshop Session:</strong></td>
<td><strong>Francisco Grande-Covian Hall</strong></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Track 2: Lipid and lipoprotein metabolism</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>2.3 THE LIVER-INTESTINE AXIS IN LIPID METABOLISM</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Chairs:</strong> TBA</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Gerhard Kostner, Austria</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>INTESTINAL TRANSPORTERS, TICE</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Bert Groen, The Netherlands</strong></td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td><strong>CHOLINE AND CARNITINE METABOLISM</strong></td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td><strong>Max Nieuwdorp, The Netherlands</strong></td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td><strong>INDUCTION OF LDL RECEPTOR MRNA DEGRADATION FACTOR HNRNPD CONTRIBUTES TO THE CHOLESTEROL-MEDIATED SUPPRESSION OF LIVER LDL RECEPTOR EXPRESSION</strong></td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td>Liu, J., USA</td>
<td></td>
</tr>
<tr>
<td>12:03</td>
<td><strong>HEPATIC DE NOVO LIPOGENESIS AND FAT OXIDATION PREDICT THE POSTPRANDIAL RESPONSE OF TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES IN HEALTHY SUBJECTS</strong></td>
<td></td>
</tr>
<tr>
<td>12:03</td>
<td>Matikainen, N., Finland</td>
<td></td>
</tr>
<tr>
<td>12:16</td>
<td><strong>RNF20 IS A KEY PLAYER IN PKA-DEPENDENT SREBP1C DEGRADATION IN HEPATIC LIPOMETABOLISM</strong></td>
<td></td>
</tr>
<tr>
<td>12:16</td>
<td>Kim, J.B., Korea</td>
<td></td>
</tr>
</tbody>
</table>
SUNDAY, JUNE 1, 2014

11:00 – 12:30  Workshop Session:  Manuel de Oya Hall
Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease
3.3 GENE-ENVIRONMENT INTERACTIONS AND EPIGENETICS
Chairs: Fernando Civeira, Spain
        Ruth Frikke-Schmidt, Denmark

11:00  GENETIC AND ENVIRONMENTAL FACTORS INFLUENCING NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS
Florian Kronenberg, Austria

11:25  MicroRNAs IN HEART DISEASE
Thomas Thum, Germany

11:50  TARGETING HDAC3 LIMITS FOAM CELL FORMATION AND IMPROVES ATHEROSCLEROTIC PLAQUE STABILITY
Van den Bossche, J., Netherlands

12:03  SIX-YEAR TELOMERE SHORTENING IS ASSOCIATED WITH INCREASED INCIDENCE OF SUBCLINICAL CAROTID VASCULAR DAMAGE AND CARDIOVASCULAR PROGNOSIS
Baragetti, A., Italy

12:16  IRON AS A RISK FACTOR FOR ATHEROSCLEROSIS: CONFIRMING THE IRON HYPOTHESIS IN A MOUSE MODEL OF HEMOCHROMATOSIS
Vinchi, F., Germany

SUNDAY, JUNE 1, 2014

11:00 – 11:45  Workshop Session:  Anitschkow Hall
Track 4: Advanced Clinical Seminars
ECTOPIC FAT AS A CARDIOVASCULAR RISK FACTOR
Chairs: Vicente Lahera, Spain
        Philippe Moulin, France

11:00  THE ROLE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN CARDIOVASCULAR DISEASE
Sven Francque, Belgium

11:20  OBESITY AND CARDIOVASCULAR RISK
Jean Pierre Després, Canada

11:40  DISCUSSION
SUNDAY, JUNE 1, 2014

11:45 – 12:30 Workshop Session: Track 4: Advanced Clinical Seminars
NEW TARGETS FOR LIPID LOWERING THERAPY
Chairs: Juan Pedro-Botet, Spain
       Chris Packard, UK

11:45 ANTISENSE NUCLEOTIDES
Mark Graham, USA

12:05 TRANSCRIPTIONAL REGULATORS
Bart Staels, France

12:25 DISCUSSION

SUNDAY, JUNE 1, 2014

12:30 - 15:00 Lunch Break, Exhibition and Poster Presentations

12:45 - 13:45 EAS General Assembly (Members Only) Amador Schuller Hall

13:50 – 14:50 Moderated Poster Session A Exhibition Area

SUNDAY, JUNE 1, 2014

13:00– 14:30 Educational Symposium (Sponsored) Not included in the CME/CPD programme Manuel de Oya Hall

14:00 – 15:00 Educational Symposium (Sponsored) Not included in the CME/CPD programme Francisco Grande-Covian Hall
SUNDAY, JUNE 1, 2014

15:00 – 16:30 Workshop Session: Anitschkow Hall

JOINT ESC/EAS SYMPOSIUM:
LIPOID LOWERING IN CARDIOVASCULAR PREVENTION; WHERE DO WE STAND AND WHERE ARE WE GOING?
Chairs: Lale Tokgözoglu, Turkey
TBA

REVIEW OF CURRENT STATUS FOR THE GUIDELINES ON DYSLIPIDEMIA – COMPARING EUROPEAN AND US GUIDELINES
Olov Wiklund, Sweden

CHALLENGES FOR FUTURE GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION
Guy de Backer, Belgium

RISK ESTIMATION AND RISK CALCULATION
TBA

LOOKING TO THE FUTURE – GUIDANCE ON LIPIDS AND OTHER TARGETS
Børge Nordestgaard, Denmark

16:30 Coffee Break and Exhibition

SUNDAY, JUNE 1, 2014

15:00 – 16:30 Workshop Session: Francisco Grande-Covian Hall

Track 1: Vascular biology of the arterial wall

1.4 ENDOTHELIAL CELL BIOLOGY
Chairs: Teresa Tejerina, Spain
Petri Kovanen, Finland

15:00 REGULATION OF ENDOTHELIAL BARRIER INTEGRITY
Asrar B.Malik, USA

15:25 LYMPHATIC VESSELS AND LYMPHANGIOGENESIS
Michael Detmar, Switzerland

15:50 TBA

16:03 THE ROLE OF ENDOTHELIAL DICER IN ATHEROSCLEROSIS
Hartmann, P., Germany

16:16 THE ADIPOKINE VISFATIN/NAMPT INDUCES PREMATURE SENESCENCE AND TELOMERE DAMAGE IN HUMAN ENDOTHELIAL CELLS
Peiro, C., Spain

16:30 Coffee Break and Exhibition
### SUNDAY, JUNE 1, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 16:30</td>
<td>Clinical &amp; Late Breaking Session I</td>
<td>Amador Schuller Hall</td>
</tr>
<tr>
<td>Chairs:</td>
<td></td>
<td>TBA</td>
</tr>
<tr>
<td>15:45</td>
<td>ATTAINMENT OF THE ANTICIPATED &gt;=50% REDUCTION IN LDL-C IN THE FOUR ACC/AHA GUIDELINES STATIN BENEFIT GROUPS: A VOYAGER META-ANALYSIS</td>
<td>Karlson, B., Sweden</td>
</tr>
<tr>
<td>15:58</td>
<td>EFFICACY OF EVOLOCUMAB (AMG 145) IN PATIENTS WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS</td>
<td>Harada-Shiba, M., Japan</td>
</tr>
<tr>
<td>16:11</td>
<td>TRIAL EVALUATING EVOLOCUMAB, A PCSK9 ANTIBODY, IN PATIENTS WITH HOMOZYGOUS FH (TESLA): RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL</td>
<td>Raal, F., South Africa</td>
</tr>
<tr>
<td>16:24</td>
<td>THERAPY WITH THE THYROID HORMONE RECEPTOR AGONIST EPROTIROME IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY</td>
<td>Sjouke, B., Netherlands</td>
</tr>
</tbody>
</table>

### SUNDAY, JUNE 1, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 18:30</td>
<td>Educational Symposium (Sponsored)</td>
<td>Francisco Grande-Covian Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:45</td>
<td>Meet the Expert (Sponsored)</td>
<td>Manuel de Oya Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:45</td>
<td>Special Lecture (Sponsored)</td>
<td>Amador Schuller Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY, JUNE 2, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Plenary Session &lt;br&gt;&lt;br&gt;Energy Metabolism and Diabetes &lt;br&gt;Chairs: Jan Borén, Sweden &lt;br&gt;Antonio Gotto, USA</td>
<td>Anitschkow Hall</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>DIABETIC DYSLIPIDEMIA &lt;br&gt;Marja-Riitta Taskinen, Finland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>REGULATION OF ADIPOGENESIS &lt;br&gt;Ulf Smith, Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>NAFLD and NASH &lt;br&gt;Philip Newsome, UK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>LIPOTOXIC HEART DISEASE &lt;br&gt;Ira Goldberg, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Coffee Break and Exhibition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker/Institution</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Workshop Session:</td>
<td>Amador Schuller Hall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Track 1: Vascular biology of the arterial wall</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.1 METABOLISM AND FUNCTIONS OF LIPOIDS IN VASCULAR CELLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: TBA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bart Staels, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>CELLULAR LIPID TRAFFICKING</td>
<td>Eli Ikonen, Finland</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>SPHINGOSINE-1-PHOSPHATE</td>
<td>Roch Nofer, Germany</td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td>LIPOPROTEIN METABOLISM AND TRANSENDOHELIAL APOLIPOPROTEIN A-I TRANSPORT IN MICE WITH AN ENDOTHELUM SPECIFIC KNOCK-OUT OF ATP BINDING CASSETTE TRANSPORTER</td>
<td>Hasballa, R., Switzerland</td>
<td></td>
</tr>
<tr>
<td>12:03</td>
<td>HIV-1 PROTEIN NEF IMPAIRS CELLULAR CHOLESTEROL EFFLUX BY DISRUPTING THE INTERACTION BETWEEN ABCA1 AND CALNEXIN</td>
<td>Bukrinsky, M., USA</td>
<td></td>
</tr>
<tr>
<td>12:16</td>
<td>PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 DEFICIENT MICE ARE PROTECTED FROM NEOINTIMA FORMATION IN CAROTID ARTERY INJURY MODE</td>
<td>Nicola, F., Italy</td>
<td></td>
</tr>
</tbody>
</table>
11:00 – 12:30 Workshop Session: Francisco Grande-Covian Hall
Track 2: Lipid and lipoprotein metabolism
2.4 REGULATION OF DEPOT FAT
Chairs: Pedro González Santos, Spain
Geesje Dallinga-Thie, The Netherlands

11:00 ABDOMINAL FAT
Peter Arner, Sweden

11:25 BROWN ADIPOSE TISSUE
Jörg Heeren, Germany

11:50 NON-CANONICAL WNT SIGNALING PROMOTES OBESITY-INDUCED ADIPOSE TISSUE INFLAMMATION AND METABOLIC DYSFUNCTION
Fuster, J., USA

12:03 THE INHIBITION OF LYSYL OXIDASE IMPROVES METABOLIC ALTERATIONS AND ADIPOSE TISSUE DISTURBANCES IN OBESE ANIMALS
Cachofeiro, Victoria, Spain

12:16 THE LOW-EXPRESSION VARIANT OF FATTY ACID-BINDING PROTEIN 4 FAVORS REDUCED MANIFESTATIONS OF ATHEROSCLEROTIC DISEASE AND INCREASED PLAQUE STABILITY
Saksi, J., Finland
MONDAY, JUNE 2, 2014

11:00 – 12:30  Workshop Session:  Manuel de Oya Hall
Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease
3.4 ENVIRONMENTAL AND METABOLIC STRESSORS IN CARDIOVASCULAR DISEASE
Chairs: Fernando Rodríguez Artalejo, Spain
       Michal Vrablik, Czech Republic

11:00  STRESS, SOCIOECONOMIC STATUS AND CARDIOVASCULAR DISEASE RISK: AN UPDATE ON CURRENT KNOWLEDGE
       Mika Kivimäki, UK

11:25  ENVIRONMENTAL AND BEHAVIOURAL RISK FACTORS
       Fernando Rodríguez-Artalejo, Spain

11:50  CIRCULATING PLASMA FIBROBLAST GROWTH FACTOR-23 IS ASSOCIATED WITH HEMORRHAGIC BUT NOT WITH ISCHEMIC STROKE: RESULTS FROM A GERMAN POPULATION STUDY
       di Giuseppe, R., Germany

12:03  LACK OF LDL-RECEPTORS PROTECTS AGAINST NEW ONSET TYPE 2 DIABETES - RESULTS OF A COHORT OF 38,000 INDIVIDUALS ANALYZED FOR FH MUTATIONS
       Besseling, J., Netherlands

12:16  PLASMA SPHINGOLIPID PROFILING REVEALS NOVEL DISTINCT BIOMARKERS FOR PREDICTING CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS
       Othman, A., Switzerland
MONDAY, JUNE 2, 2014

11:00 – 12:30  Workshop Session:  
Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease  
3.2 NUTRITION AND NUTRACEUTICALS  
Chairs: Emilio Ros, Spain  
Paul Nestel, Australia

11:00  MEDITERRANEAN DIET  
Emilio Ros, Spain

11:25  NUTRIGENOMICS AND FUNCTIONAL FOODS  
Helena Gylling, Finland

11:50  EFFECT OF A MEDITERRANEAN DIET INTERVENTION ON 3T MRI-MONITORED CAROTID PLAQUE PROGRESSION AND VULNERABILITY. A SUB-STUDY OF THE PREDIMED TRIAL.  
Sala-Vila, A., Spain

12:03  IS COMPLYING WITH THE RECOMMENDATIONS OF SODIUM INTAKE BENEFICIAL FOR HEALTH? EVIDENCE FROM THE PREDIMED STUDY  
Merino, J., Spain

12:16  "CHILDHOOD 25-OH-VITAMIN D LEVELS AND CAROTID INTIMA-MEDIA THICKNESS IN ADULTHOOD. THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY."  
Juonala, M., Finland

MONDAY, JUNE 2, 2014

12:30 - 15:00  Lunch Break, Exhibition and Poster Presentations  
Exhibition Area

12:45 – 13:45  Moderated Poster Session B  
Exhibition Area

13:50 – 14:50  Moderated Poster Session C  
Exhibition Area

13:00 – 14:30  Educational Symposium (Sponsored)  
Not included in the CME/CPD programme  
Manuel de Oya Hall

14:00 – 15:00  Educational Symposium (Sponsored)  
Not included in the CME/CPD programme  
Francisco Grande-Covian Hall

15.00 - 16:30  Poster Award Competition  
Exhibition Area
15:00 – 16:30 Joint ICCR/EAS Workshop

TARGETING LIFESTYLE IN CVD RISK MANAGEMENT / PREVENTION

Chairs: Gabrielle Riccardi, Italy
       Frank B. Hu, USA

OPENING REMARKS
Gabrielle Riccardi, Italy

FROM NUTRIENTS TO FOOD: KEY FEATURES OF OUR DIET PROVIDING CARDIO PREVENTION
Frank B. Hu, USA

LESSONS FROM THE PREDIMED TRIAL
Emilio Ros, Spain

LESSONS FROM LOOK AHEAD
Jean-Pierre Després, Canada

PHYSICAL ACTIVITY AND CVD RISK
Rainer Rauramaa, Finland
MONDAY, JUNE 2, 2014

15:00 – 16:30 Workshop Session Francisco Grande-Covian Hall
Track 2: Lipid and lipoprotein metabolism

2.2 NOVEL PROTECTIVE EFFECTS OF HDL
Chairs: Arnold von Eckardstein, Switzerland
        Miranda Van Eck, The Netherlands

15:00 THERAPEUTIC POTENTIAL OF HDL IN CARDIOPROTECTION, CARDIAC REMODELLING, AND HEART FAILURE
Bart de Geest, Belgium

15:25 HDL AND ABCA1 IN THE BRAIN
Cheryl Wellington, Canada

15:50 A LOSS-OF-FUNCTION MUTATION IN SCARB1 SEVERELY IMPAIRS SR-BI PROCESSING AND ACTIVITY IN HUMANS
Zanoni, P., USA

16:03 NOVEL HDL FUNCTIONS ASSOCIATED WITH INTERCELLULAR COMMUNICATION, Atherosclerosis, and CHRONIC KIDNEY DISEASE
Vickers, K., USA

16:16 APOLIPOPROTEIN A-I MIMETIC PEPTIDE 4F BLOCKS SPHINGOMYELINASE-INDUCED LDL AGGREGATION: INTERACTION OF THE AMPHIPATHIC HELICAL PEPTIDE WITH LDL PARTICLES
Nguyen, S., Finland
MONDAY, JUNE 2, 2014

15:00 - 16:30  EAS Initiatives Update Session (Open to All)  Manuel de Oya Hall
Chair:  Alberico Catapano, Italy
       Olov Wiklund, Sweden

INTRODUCTION/ GENERAL OVERVIEW
Alberico Catapano, Italy

EDUCATIONAL ACTIVITIES
* ACCREDITED DIPLOMA COURSE,
* EAS ACADEMY
* ADVANCED COURSES
Lale Tokgozoglu, Turkey

CONSENSUS POSITION PAPERS
* PLANT STANOLS AND PLANT STEROLS
* TRIGLYCERIDES
* HOMOZYGOUS FH
* STATIN INTOLERANCE
John Chapman, France

MONDAY, JUNE 2, 2014

15.00 - 15.45  YOUNG INVESTIGATOR AWARD SESSION  Amador Schuller Hall

MONDAY, JUNE 2, 2014

15:45 - 16.30  CLINICAL & LATE BREAKING SESSION II  Amador Schuller Hall

15:45
RECOMBINANT HUMAN APOLIPOPROTEIN-A-I PREBETA-HDL (CER-001) PROMOTES REVERSE
CHOLESTEROL TRANSPORT AND REDUCES CAROTID WALL THICKNESS IN PATIENTS WITH
GENETICALLY-DETERMINED LOW HDL
Smits, L., Netherlands

15:58
TBA

16:11
MUTATIONS IN ABCA1 ARE ASSOCIATED WITH ENHANCED BETA-CELL SECRETORY CAPACITY
IN HUMANS
Cuchel, M., USA

16:24
TBA
### 82nd EAS Congress Scientific Programme

**MONDAY, JUNE 2, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 17:00</td>
<td>Coffee Break, Exhibition and Poster Viewing</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>Educational Symposium (Sponsored)</td>
<td>Francisco Grande-Covian Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:45</td>
<td>Special Lecture (Sponsored)</td>
<td>Amador Schuller Hall</td>
</tr>
<tr>
<td></td>
<td>Not included in the CME/CPD programme</td>
<td></td>
</tr>
</tbody>
</table>
# TUESDAY, JUNE 3, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:30</td>
<td>Plenary Session: &lt;br&gt;<strong>RISK FACTORS AND INTERVENTIONS</strong> &lt;br&gt;Chairs: Olov Wiklund, <em>Sweden</em>&lt;br&gt;John Chapman, <em>France</em></td>
</tr>
<tr>
<td>08:30</td>
<td>CLASSICAL AND NOVEL RISK FACTORS &lt;br&gt;<em>Naveed Sattar, UK</em></td>
</tr>
<tr>
<td>09:00</td>
<td>GENETIC RISK FACTORS AND MENDELIAN RANDOMIZATION&lt;br&gt;<em>Anne Tybjaerg-Hansen, Denmark</em></td>
</tr>
<tr>
<td>09:00</td>
<td>RESIDUAL CARDIOVASCULAR RISK: MANAGEMENT BEYOND STATINS&lt;br&gt;<em>Jane Armitage, UK</em></td>
</tr>
<tr>
<td>09:30</td>
<td>PCSK9 INHIBITION&lt;br&gt;<em>Bertrand Cariou, France</em></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Coffee Break, Poster Viewing and Exhibition</td>
</tr>
</tbody>
</table>
11:00 – 12:30 Workshop Session: Track 1: Vascular biology of the arterial wall

1.3 PLASTICITY OF ATHEROSCLEROTIC LESIONS
Chairs: Lina Badimón, Spain
Andrew Newby, UK

11:00 METALLOPROTEINASES
Andrew Newby, UK

11:25 MACROPHAGE TRAFFICKING
Gwendalyn Randolph, USA

11:50 FORKHEAD TRANSCRIPTION FACTOR FOXO3A POTENTLY INDUCES SMOOTH MUSCLE CELL APOPTOSIS AND PROMOTES EXTRACELLULAR MATRIX DEGRADATION THROUGH ACTIVATION OF MATRIX METALLOPROTEINASES
Yu, H., United Kingdom

12:03 HEAT SHOCK PROTEIN 27 IS A NOVEL Athero-Biomarker That Halts Atherosclerotic Lesion Progression and Enhances Lesion Remodeling
O'Brien, E., Canada

12:16 TBA
TUESDAY, JUNE 3, 2014

11:00 – 12:30 Workshop Session:  
Track 2: Lipid and lipoprotein metabolism  
2.1 GENOMICS AND PROTEOMICS OF LIPID METABOLISM  
Chairs: TBA  
Steve Humphries, UK

11:00 GENOMICS (GWAS)  
Marcello Arca, Italy

11:25 STRUCTURE-FUNCTION RELATIONSHIPS ACROSS HDL PARTICLES AS REVEALED BY PROTEOMICS AND LIPIDOMICS  
Anatol Kontush, France

11:50 MUTATIONS IN STAP1 ARE ASSOCIATED WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA  
Fouchier, S., Netherlands

12:03 LOSS-OF-FUNCTION MUTATIONS IN APOC3 AND REDUCED RISK OF ISCHEMIC VASCULAR DISEASE  
Tybjaerg-Hansen, A. Denmark

12:16 GENETIC DEFECTS IN PROTEIN GLYCOSYLATION AS A CAUSE OF DYSLIPIDEMIA  
vander Boogert, M., Netherlands
TUESDAY, JUNE 3, 2014

11:00 – 12:30  Workshop Session:  
Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease

**3.1 HYPOLIDAEMIC DRUGS PRESENT AND FUTURE**

Chairs: Rafael Carmena, Spain  
Anders Olsson, Sweden

11:00  STATE OF THE ART IN LIPID LOWERING THERAPY  
Rafael Carmena, Spain

11:25  FUTURE DEVELOPMENTS OF LIPID LOWERING DRUGS  
Alberto Corsini, Italy

11:50  EFFECT OF ROSUVASTATIN THERAPY ON CAROTID INTIMA MEDIA THICKNESS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: FINDINGS FROM THE CHARON STUDY  
Braamskamp, M., Netherlands

12:03  ALIROCUMAB, MONOCLONAL ANTIBODY TO PCSK9, DOSE-DEPENDENTLY DECREASES ATHEROSCLEROSIS, IMPROVES PLAQUE STABILITY AND SHOWS ADDITIVE EFFECTS WITH ATORVASTATIN IN APOE*3LEIDEN.CETP MICE  
Van der Hoorn, J., Netherlands

12:16  EFFECT OF SEBELIPASE ALFA AFTER 90 WEEKS IN ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY  
Tripuraneni, R., USA

TUESDAY, JUNE 3, 2014

11:00 – 11:45  Workshop Session:  
Track 4: Advanced Clinical Seminars

**4.1 IMAGING OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE**

Chair: Xavier Pinto, Spain  
Gil Thompson, UK

11:00  EPIDEMIOLOGICAL AND CLINICAL EVIDENCE IN FAVOUR OR AGAINST CLINICAL UTILITY OF DIFFERENT PROCEDURES  
Dan O’Leary, USA

11:20  NOVEL METHODS  
Erik Stroes, The Netherlands

11:40  DISCUSSION
11:45 – 12:30 Workshop Session: Anitschkow Hall
Track 4: Advanced Clinical Seminars
4.2 OPTIMIZING TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA
Chair: TBA
Børge Nordestgaard, Denmark

11:45 TREATMENT OF ADULTS
Luis Masana, Spain

12:05 TREATMENT OF CHILDREN AND ADOLESCENTS
Albert Wiegman, The Netherlands

12:25 DISCUSSION